8-K/A: 2seventy bio Completes Oncology and Autoimmune Pipeline Divestiture to Regeneron, Shifts Focus to Abecma

2seventy bio has finalized the sale of its oncology and autoimmune pipeline to Regeneron, and will now concentrate on the development and commercialization of Abecma.

Summary

• 2seventy bio has completed the sale of its oncology and autoimmune research and development programs to Regeneron Pharmaceuticals for an upfront payment of $5 million.
• Regeneron also assumed certain liabilities and will pay a $10 million milestone payment upon the first regulatory approval or commercial sale of a product from the acquired assets.
• Additionally, 2seventy bio will receive royalty payments on net sales of any commercialized products from the divested pipeline.
• The company has entered into sublease agreements with Regeneron for facilities in Seattle and Cambridge.
• 2seventy bio will now focus exclusively on Abecma, its CAR T-cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb.
• The company has reduced its workforce to approximately 65 full-time employees, primarily in quality and supporting functions.
• These strategic actions have extended 2seventy bio's cash runway beyond 2027.
• The pro forma financial statements reflect a loss on the divestiture of $4.893 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the divestiture and focus on Abecma could be positive, the loss on divestiture and reliance on a single product introduce significant risks. The extended cash runway is a positive, but the overall sentiment is cautiously optimistic.

Positives

• The sale of the oncology and autoimmune pipeline provides immediate cash and potential future revenue through milestones and royalties.
• The company's focus on Abecma allows for a more streamlined and targeted approach.
• The reduction in workforce and associated cost savings have extended the company's cash runway beyond 2027.
• The company retains a focus on quality control of lentiviral vector (LVV) for Abecma.
• Nick Leschly will continue to contribute to the company as Chairman of the Board.

Negatives

• The company incurred a loss of $4.893 million on the divestiture of the R&D pipeline.
• The company has significantly reduced its workforce, which may impact morale and operations.
• The company is now reliant on the success of a single product, Abecma.
• The company is dependent on Bristol Myers Squibb for the commercialization of Abecma.

Risks

• The commercial success of Abecma is not guaranteed.
• Regulatory approval for Abecma in earlier lines is not guaranteed.
• The strategic realignment may not achieve the anticipated cost savings.
• The company may face challenges in managing operating expenses and cash use.
• The company is dependent on the success of a single product, Abecma, which increases risk.

Future Outlook

2seventy bio will focus exclusively on the development and commercialization of Abecma, with the goal of bringing it to more patients in earlier lines of treatment. The company anticipates a longer cash runway due to cost savings and the sale of the pipeline assets.

Management Comments

• Chip Baird, CEO, stated that the company is excited about its future with the potential to bring Abecma to more patients.
• Chip Baird, CEO, mentioned that the company is pleased to have successfully transitioned its innovative cell therapy pipeline to Regeneron.

Industry Context

The divestiture of the oncology and autoimmune pipeline and the focus on Abecma reflects a strategic shift in the company's direction. This move is likely influenced by the competitive landscape in the cell therapy space and the need to focus resources on a core asset. The collaboration with Bristol Myers Squibb for Abecma is a key factor in this strategy.

Comparison to Industry Standards

• The divestiture of early-stage research programs to focus on a single commercial product is a strategy seen in other biotech companies facing financial constraints or seeking to streamline operations, such as bluebird bio's decision to focus on its gene therapy products.
• The upfront payment of $5 million for a pipeline of assets is relatively low, suggesting that the value of the assets was primarily in their potential rather than current revenue generation, similar to other early-stage biotech asset sales.
• The milestone payment of $10 million and royalty structure is a common approach in biotech asset sales, allowing the seller to participate in the future success of the divested assets, similar to the structure of many pharmaceutical licensing agreements.
• The reduction in workforce to 65 employees is a significant downsizing, which is not uncommon for companies undergoing strategic realignments, similar to the restructuring seen in companies like Sangamo Therapeutics.
• The extension of the cash runway beyond 2027 is a positive outcome, but the company's future is now heavily reliant on the success of Abecma, which is a high-risk, high-reward strategy, similar to other companies with a single lead product.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the strategic shift, but could benefit from the long-term success of Abecma.
• Employees have been significantly impacted by the workforce reduction, with approximately 160 employees joining Regeneron.
• Customers (patients) may benefit from the increased focus on Abecma and its potential to reach more patients.
• Suppliers may see changes in demand due to the shift in focus.
• Creditors may be impacted by the company's financial restructuring.

Next Steps

• 2seventy bio will focus on the commercialization and development of Abecma.
• The company will continue to support quality control of lentiviral vector (LVV) for Abecma.
• The company will work with Bristol Myers Squibb to expand the reach of Abecma.

Key Dates

Keywords

2seventy bio, Regeneron, Abecma, CAR T-cell therapy, oncology, autoimmune, asset sale, milestone payment, royalty, divestiture, multiple myeloma, cell therapy